Immunosuppressive acidic protein in malignant diseases. Clinical relevance? 1991

S Glück, and W Köster
Department of Hematology, Heinrich-Heine-Universität, Düsseldorf, FRG.

The immunosuppressive acidic protein (IAP) has been described as a tumor associated marker in some solid tumors and hematologic diseases. To define the clinical relevance the authors determined the serum IAP levels in 194 patients with malignancies before initiation of therapy, 14 patients with idiopathic thrombocytopenic purpura (ITP), 28 patients with bacterial pneumonia, and 23 healthy volunteers. Immunosuppressive acidic protein was measured by radial immunodiffusion. The mean value of our controls was 405 +/- 48 micrograms/ml. This is consistent with published data. The mean values for patients with malignancies varied from 554 micrograms/ml to 698 micrograms/ml. These are only marginally higher than those observed for the controls. In contrast patients with bacterial pneumonia demonstrated significantly elevated values (1038 +/- 261 micrograms/ml). The authors conclude that IAP cannot be used as a diagnostic marker for the malignant diseases examined in this study.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011696 Purpura, Thrombocytopenic Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms. Purpura, Thrombopenic,Purpuras, Thrombocytopenic,Purpuras, Thrombopenic,Thrombocytopenic Purpura,Thrombocytopenic Purpuras,Thrombopenic Purpura,Thrombopenic Purpuras
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

S Glück, and W Köster
November 1988, Rinsho byori. The Japanese journal of clinical pathology,
S Glück, and W Köster
October 1985, Nihon Gan Chiryo Gakkai shi,
S Glück, and W Köster
March 1986, Bulletin of the Chest Disease Research Institute, Kyoto University,
S Glück, and W Köster
April 1992, Nippon Ganka Gakkai zasshi,
S Glück, and W Köster
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
S Glück, and W Köster
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
S Glück, and W Köster
March 1988, Hinyokika kiyo. Acta urologica Japonica,
S Glück, and W Köster
February 1988, American journal of ophthalmology,
S Glück, and W Köster
January 1994, Japanese journal of ophthalmology,
Copied contents to your clipboard!